BIO-RAD LABORATORIES, INC.
BIOAPI behind this page
BIO Q1 2026 request
Playground key active
/api/financials?ticker=BIO&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 592.1 | 585.4 | +1.1% |
Show Business Segments breakouts |
|||
| Clinical Diagnostics | 363.6 | 356.8 | +1.9% |
| Life Science | 228.5 | 228.6 | -0.0% |
Show Geography breakouts |
|||
| Americas | 45.1 | 39.8 | +13.3% |
| Asia Pacific | 110.4 | 104.1 | +6.1% |
| Europe | 206.8 | 199.8 | +3.5% |
| US | 229.8 | 241.7 | -4.9% |
| Cost of Revenue | 282.7 | 279.4 | +1.2% |
Show Business Segments breakouts |
|||
| Clinical Diagnostics | 181.8 | 179.2 | +1.5% |
| Life Science | 100.9 | 100.2 | +0.7% |
| Gross Profit | 309.4 | 306 | +1.1% |
Show Business Segments breakouts |
|||
| Clinical Diagnostics | 181.8 | 177.6 | +2.4% |
| Life Science | 127.6 | 128.4 | -0.6% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 309.4 | 306 | +1.1% |
| Selling, General & Administrative | 212.4 | 208.8 | +1.7% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 212.4 | 208.8 | +1.7% |
| Research & Development | 62.9 | 73.5 | -14.4% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 62.9 | 73.5 | -14.4% |
| Operating Income | 34.1 | 23.7 | +43.9% |
| Interest Expense | 12.3 | 12 | +2.5% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 12.3 | 12 | +2.5% |
| Foreign Currency Transaction Gain Loss Before Tax | -2.4 | -2.7 | +11.1% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | -2.4 | -2.7 | +11.1% |
| Marketable Securities Unrealized Gain Loss | 738.2 | -31.8 | +2421.4% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 738.2 | -31.8 | +2421.4% |
| Other Non-Operating Income (Expense) | 24.2 | 37.2 | -34.9% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | -0.3 | -0.2 | -50.0% |
| Accumulated Net Unrealized Investment Gain Loss · Reclassification Out Of Accumulated Other Comprehensive Income | 0.6 | 0.5 | +20.0% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 24.2 | 37.2 | -34.9% |
| Income Before Taxes | -689.8 | 83.4 | -927.1% |
| Income Tax Expense (Benefit) | 162.7 | -19.4 | +938.7% |
| Net Income | -527.1 | 64 | -923.6% |
Show Equity Components breakouts |
|||
| Retained Earnings | -527.1 | 64 | -923.6% |
| EPS (Basic) | -19.55 | 2.29 | -953.7% |
| Wtd Avg Shares (Basic) | 26,958 | 27,941 | -3.5% |
| EPS (Diluted) | -19.55 | 2.29 | -953.7% |
| Wtd Avg Shares (Diluted) | 26,958 | 27,955 | -3.6% |
| Other Comprehensive Income | -46.3 | 128.4 | -136.1% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -46.3 | 128.4 | -136.1% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 507.2 | 521.4 | -2.7% |
| Short-Term Investments | 1,057.5 | — | — |
| Accounts Receivable | 426.2 | — | — |
| Inventory | 770.5 | — | — |
| Prepaid Expense Current | 150 | — | — |
| Other Assets Current | 30.7 | — | — |
| Total Current Assets | 2,942.1 | — | — |
| Non-Current Assets | |||
| Operating Lease Right-of-Use Assets | 161.9 | — | — |
| Goodwill | 577.1 | — | — |
Show Business Segments breakouts |
|||
| Clinical Diagnostics | 128.4 | — | — |
| Life Science | 448.7 | — | — |
| Long Term Investments | 5,311.8 | — | — |
| Total Assets | 9,790 | — | — |
Show Business Segments breakouts |
|||
| Clinical Diagnostics · Operating Segments | 468.8 | 482 | -2.7% |
| Life Science · Operating Segments | 301.7 | 308.1 | -2.1% |
| Intangible Assets (Q) | — | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Relationships | 7.4 | 7 | +5.7% |
| Developed Technology Rights | 149.8 | 72.8 | +105.8% |
| Licensing Agreements | 8.7 | 12.2 | -28.7% |
| Noncompete Agreements | 0.1 | 0.7 | -85.7% |
| Trade Names | 0.8 | 1.1 | -27.3% |
| Other Assets | |||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 527.5 | — | — |
| Intangible Assets Net Excluding Goodwill | 166.8 | — | — |
| Other Assets | 102.8 | — | — |
| Current Liabilities | |||
| Accounts Payable | 133.1 | 137.9 | -3.5% |
| Employee Related Liabilities Current | 148.4 | 157.4 | -5.7% |
| Notes And Loans Payable Current | 400.5 | 1.2 | +33275.0% |
| Taxes Payable Current | 44.9 | 37.1 | +21.0% |
| Operating Lease Liability Current | 36.2 | 41.3 | -12.3% |
| Other Liabilities Current | 153.9 | 131.7 | +16.9% |
| Total Current Liabilities | 917 | 506.6 | +81.0% |
| Deferred Revenue | 56.3 | 53.8 | +4.6% |
| Non-Current Liabilities | |||
| Long-Term Debt | 802.9 | — | — |
| Deferred Tax Liabilities | 881.8 | 840.8 | +4.9% |
| Operating Lease Liabilities | 138.6 | 126.3 | +9.7% |
| Other Non-Current Liabilities | 198.4 | 173.1 | +14.6% |
| Total Liabilities | 2,938.7 | 2,847.5 | +3.2% |
| Long-Term Debt | 1,203.4 | — | — |
Show Debt Instrument breakouts |
|||
| Other Long-Term Debt · Other Long-Term Debt | 9.9 | 9 | +10.0% |
| Senior Notes · Senior Notes | 1,193.5 | 1,191.7 | +0.2% |
| Stockholders' Equity | |||
| Additional Paid-In Capital | 490.5 | 475.7 | +3.1% |
| Treasury Stock Value (Q) | — | — | — |
Show Statement Class Of Stock breakouts |
|||
| Treasury Stock Common | -1,053 | -866.9 | -21.5% |
| Retained Earnings | 7,649.2 | 7,480.4 | +2.3% |
| Accumulated Other Comprehensive Income | -235.4 | -409.8 | +42.6% |
| Total Stockholders' Equity | 6,851.3 | 6,679.4 | +2.6% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | 5.1 | -2 | +355.0% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | 1.2 | — | — |
| Accumulated Net Unrealized Investment Gain Loss | 5.7 | 9 | -36.7% |
| Accumulated Other Comprehensive Income | -235.4 | -409.8 | +42.6% |
| Accumulated Translation Adjustment | -247.4 | -416.8 | +40.6% |
| Additional Paid In Capital | 490.5 | 475.7 | +3.1% |
| Retained Earnings | 7,649.2 | 7,480.4 | +2.3% |
| Treasury Stock Common | -1,053 | -866.9 | -21.5% |
| Total Liabilities & Equity | 9,790 | 9,526.9 | +2.8% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Proceeds From Customers | 614.1 | 640 | -4.0% |
| Payments To Suppliers And Employees | -515.8 | -488 | -5.7% |
| Interest Paid | -22.4 | -22.2 | -0.9% |
| Income Taxes Paid | -11 | -7.9 | -39.2% |
| Proceeds From Other Operating Activities | 33.3 | 16.3 | +104.3% |
| Paymentsforproceedsfromderivativeinstrumentsoperatingactivities | 9.9 | -8.3 | +219.3% |
| Net Cash from Operations | 108.1 | 129.9 | -16.8% |
| Depreciation & Amortization (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Clinical Diagnostics | 22.6 | 21.1 | +7.1% |
| Life Science | 18.3 | 17 | +7.6% |
| Stock-Based Compensation | 15 | 15.3 | -2.0% |
| Change in Accounts Receivable | 30.8 | 37.2 | -17.2% |
| Change in Inventory | -29.9 | -17.9 | -67.0% |
| Change in Other Liabilities | 2 | -4.8 | +141.7% |
| Investing Activities | |||
| Capital Expenditures | -30 | -34.4 | +12.8% |
| Proceeds From Sale Of Property Plant And Equipment | 0.1 | — | — |
| Payments To Acquire Investments | -226.1 | -153.4 | -47.4% |
| Proceeds From Sale Of Available For Sale Securities Debt | 145.1 | 171.2 | -15.2% |
| Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | 17.7 | 19.5 | -9.2% |
| Net Cash from Investing | -93.2 | 2.9 | -3313.8% |
| Financing Activities | |||
| Repayments Of Long Term Debt | -0.1 | -0.1 | 0.0% |
| Proceeds From Issuance Of Common Stock | 3.4 | 4.3 | -20.9% |
| Share Repurchases | -47.8 | -101.9 | +53.1% |
| Option Premium Proceeds For Structured Purchases Of Treasury Stock | 0.5 | — | — |
| Net Cash from Financing | -44 | -97.7 | +55.0% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 5.9 | -1.8 | +427.8% |
| Net Change in Cash | -23.2 | 33.3 | -169.7% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 509 | 523.1 | -2.7% |
| Restricted Cash Current | 1.6 | 1.3 | +23.1% |
| Restricted Cash Noncurrent | 0.2 | 0.4 | -50.0% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.